VIVJOA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vivjoa, and what generic alternatives are available?
Vivjoa is a drug marketed by Mycovia Pharms and is included in one NDA. There are five patents protecting this drug.
This drug has sixty-three patent family members in twenty-three countries.
The generic ingredient in VIVJOA is oteseconazole. One supplier is listed for this compound. Additional details are available on the oteseconazole profile page.
DrugPatentWatch® Generic Entry Outlook for Vivjoa
Vivjoa will be eligible for patent challenges on April 26, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 17, 2036. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for VIVJOA
| International Patents: | 63 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 23 |
| Patent Applications: | 36 |
| Drug Prices: | Drug price information for VIVJOA |
| What excipients (inactive ingredients) are in VIVJOA? | VIVJOA excipients list |
| DailyMed Link: | VIVJOA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VIVJOA
Generic Entry Date for VIVJOA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for VIVJOA
US Patents and Regulatory Information for VIVJOA
VIVJOA is protected by five US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of VIVJOA is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting VIVJOA
Antifungal compounds and processes for making
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Metalloenzyme inhibitor compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: VIVJOA IS INDICATED TO REDUCE THE INCIDENCE OF RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC) IN FEMALES WITH A HISTORY OF RVVC WHO ARE NOT OF REPRODUCTIVE POTENTIAL
Metalloenzyme inhibitor compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Metalloenzyme inhibitor compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: VIVJOA IS INDICATED TO REDUCE THE INCIDENCE OF RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC) IN FEMALES WITH A HISTORY OF RVVC WHO ARE NOT OF REPRODUCTIVE POTENTIAL
Antifungal compounds and processes for making
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
FDA Regulatory Exclusivity protecting VIVJOA
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial
GENERATING ANTIBIOTIC INCENTIVES NOW
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mycovia Pharms | VIVJOA | oteseconazole | CAPSULE;ORAL | 215888-001 | Apr 26, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Mycovia Pharms | VIVJOA | oteseconazole | CAPSULE;ORAL | 215888-001 | Apr 26, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Mycovia Pharms | VIVJOA | oteseconazole | CAPSULE;ORAL | 215888-001 | Apr 26, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Mycovia Pharms | VIVJOA | oteseconazole | CAPSULE;ORAL | 215888-001 | Apr 26, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Mycovia Pharms | VIVJOA | oteseconazole | CAPSULE;ORAL | 215888-001 | Apr 26, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VIVJOA
When does loss-of-exclusivity occur for VIVJOA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 16233113
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 2017018823
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 78339
Estimated Expiration: ⤷ Try a Trial
China
Patent: 7428724
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 71347
Estimated Expiration: ⤷ Try a Trial
Eurasian Patent Organization
Patent: 7556
Estimated Expiration: ⤷ Try a Trial
Patent: 1792067
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 71347
Estimated Expiration: ⤷ Try a Trial
Finland
Patent: 71347
Estimated Expiration: ⤷ Try a Trial
Lithuania
Patent: 71347
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 17012021
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 71347
Estimated Expiration: ⤷ Try a Trial
South Korea
Patent: 170129895
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 26063
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering VIVJOA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Korea | 101379370 | ⤷ Try a Trial | |
| India | 6792DEN2014 | ⤷ Try a Trial | |
| Slovenia | 3271347 | ⤷ Try a Trial | |
| Lithuania | 3271347 | ⤷ Try a Trial | |
| Canada | 2861339 | COMPOSES INHIBITEURS DE METALLOENZYMES (METALLOENZYME INHIBITOR COMPOUNDS) | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
